Navigation Links
Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
Date:1/29/2009

BEDFORD, Ohio, Jan. 29 /PRNewswire-FirstCall/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced the launch of Irinotecan HCl Injection. This product is AP rated and is equivalent to Camptosar(R). Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. This product is available for immediate shipment nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

Bedford Laboratories will supply Irinotecan HCl Injection as a sterile aqueous solution available in two different dosages including 40mg / 2mL single dose amber vials individually boxed and 100mg / 5mL single dose amber vials individually boxed.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169 or from their web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and international markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.

Camptosar(R) is a registered trademark of Pfizer.


'/>"/>
SOURCE Bedford Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
2. Children of New Bedford Immigrant Raids Are Victims of Terrorism, Testifies Dr. Laria Today
3. ADDA Kicks Off AD/HD Awareness Campaign with Four Regional Conferences Beginning Sept. 29 and Series of Fall Teleclasses
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
6. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Most comprehensive study of mercury in dental fillings begins
9. Eye Safety Begins at Home
10. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
11. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Arkansas that offers insurance and financial preparation services, is providing an update on ... Rescue organization. , Rock City Rescue is a locally recognized nonprofit that provides ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) ... and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton ... until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology: